ACST stock news

Shares of Acasti Pharma Inc (NASDAQ: ACST ), which closed at $2.18 Friday, have entered penny stock territory after a negative data readout. Placebo Effect Impacts Acasti's Results Acasti released topline results Monday from a Phase 3 study dubbed TRILOGY 1 that evaluated its lead candidate CaPre, or omega-3 phospholipid, for the treatment of hypertriglyceridemia. The experimental drug did not achieve statistical significance in meeting the primary endpoint. This was due to unusually large placebo effect, according to the company. CaPre reduced triglyceride by 30% from the baseline at 12 weeks and by 36.7% at 26 weeks, the company said. The control arm receiving placebo showed a 27.5% mean reduction in triglyceride levels at 12 weeks and a 28% mean reduction at week 26. Patients receiving CaPre while on background statin therapy showed a 42.2% mean reduction in triglyceride at 12 weeks compared to 31.5% for … Full story available on Benzinga.com Read more

AstraZeneca and Acasti Pharma each disclosed disappointing results from cardiovascular drugs derived from fish or krill oil. Amarin’s stock took off. Read more

Stocks that moved substantially or traded heavily on Tuesday: Uber, Lennar and Freeport-McMoRan rise; Acasti Pharma slides Read more

Acasti Pharma (ACST) is having trouble on Monday as ACST stock has fallen a great deal, but what's behind the falling prices? Read more

The company announced that the last patient completed their final visit in its TRILOGY 1 pivotal Phase 3 clinical trial of CaPre. The post Acasti Pharma Updates on TRILOGY 1 Phase 3 Trial appeared first on Investing News Network . Read more

Dover, Delaware--(Newsfile Corp. - November 25, 2019) - Encode Ideas, L.P. Initiates Research on Acasti Pharma, Inc. (NASDAQ: ACST). The full research publication is available here and available on our website at www.encodelp.com. Encode Ideas is initiating coverage on Acasti Pharma, Inc. as a high-risk Read more

According to the announcement, CaPre demonstrated insulin secretion, which its counterpart metformin is not able to do. The post Acasti Pharma Releases Preliminary Data for CaPre in Diabetic Mice appeared first on Investing News Network . Read more

LAVAL, Québec, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of Read more

LAVAL, Québec, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Medpace Holdings Inc (NASDAQ: MEDP )(reported strong second-quarter results ) Novocure Ltd (NASDAQ: NVCR ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 30) Alimera Sciences Inc (NASDAQ: ALIM )(reacted to second-quarter results) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Equillium Inc (NASDAQ: EQ ) Medtronic PLC (NYSE: MDT ) Obseva SA (NASDAQ: OBSV ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Stocks In Focus Roche Extends Offer Period For Spark Buy Once Again Roche Holdings AG Basel ADR (OTC: RHHBY ) and Spark Therapeutics Inc (NASDAQ: ONCE ) announced Wednesday Roche has extended the offering period for its previously announced tender offer to buy all outstanding shares of Spark for $114.50 … Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) Acasti Pharma Inc (NASDAQ: ACST ) Array Biopharma Inc (NASDAQ: ARRY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 18) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Hologic, Inc. (NASDAQ: HOLX ) Novocure Ltd (NASDAQ: NVCR ) Odonate Therapeutics Inc (NASDAQ: ODT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 29) Acer Therapeutics Inc (NASDAQ: ACER ) Advaxis, Inc. (NASDAQ: ADXS ) Cancer Genetics Inc (NASDAQ: CGIX ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Genprex Inc (NASDAQ: GNPX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX )(slumped in reaction to Sanofi SA (NASDAQ: SNY )'s decision to terminate their collaboration agreement regarding sotagliflozin that is being evaluated for Type 2 diabetes) Myovant Sciences Ltd (NYSE: MYOV ) Neovasc Inc (NASDAQ: NVCN ) Neon Therapeutics Inc (NASDAQ: NTGN ) Neuralstem, Inc. (NASDAQ: CUR ) Novavax, Inc. (NASDAQ: NVAX ) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) Personalis Inc (NASDAQ: PSNL )( IPOed June 20) Cytori Therapeutics (NASDAQ: PSTV ) Proteostasis Therapeutics Inc (NASDAQ: PTI ) Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Unity Biotechnology Inc (NASDAQ: UBX ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Wave Life Sciences Ltd (NASDAQ: WVE ) (reacted … Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems Inc (NASDAQ: CSII ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Masimo Corporation (NASDAQ: MASI ) VolitionRX Ltd (NYSE: VNRX ) Edwards Lifesciences Corp (NYSE: EW )(reported a beat-and-raise second quarter) Haemonetics Corporation (NYSE: HAE ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 24) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) GENFIT S A/ADR (NASDAQ: GNFT ) ContraVir Pharmaceuticals Inc (NASDAQ: HEPA) Innoviva Inc (NASDAQ: INVA ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) Neovasc Inc (NASDAQ: NVCN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pluristem Therapeutics Inc. (NASDAQ: PSTI )(announced 1-for-10 reverse stock split) Regulus Therapeutics Inc (NASDAQ: RGLS )(FDA imposed partial clinical hold on its kidney disease drug) Surface Oncology Inc (NASDAQ: SURF ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Wave Life Sciences Ltd (NASDAQ: WVE ) Stocks In Focus FDA Approves Lilly's Nasally-Administered Low Blood Sugar Drug Eli Lilly And Co (NYSE: LLY ) said the FDA has approved its Baqsimi, the first and only nasally administered glucagon to treat severe hypoglycemia in a single, fixed, 3mg dose. Read more

Shares of biopharmaceutical company Acasti Pharma Inc (NASDAQ: ACST ) were trading higher Wednesday after the biopharmaceutical company issued a fiscal 2019 year-end business update. What Happened Acasti , a biopharma innovator focused on the treatment of severe hypertriglyceridemia (HTG), said in a business update that fiscal 2019 was "eventful." The company recorded milestones related to its Phase 3 clinical trials and achieved 100% patient randomization in the TRILOGY clinical trials. Acasti's loss for fiscal 2019 expanded from $21.5 million in the prior … Full story available on Benzinga.com Read more

LAVAL, Québec, May 10, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced that it has settled regarding claims made against the Company by its former chief executive officer (the “Former CEO”) in respect of the termination of his employment Read more

Read more